Ansari and Luba Katz of Abt Associates in Cambridge, Mass., reported their results in "Survey of Patient Release Information on Radiation and Security Checkpoints," which appears in the December issue of the Journal of Nuclear Medicine, which is published by SNM, the world's largest molecular imaging and nuclear medicine society.

Nuclear medicine-a vital component of the rapidly emerging field of molecular imaging-is a medical specialty that uses small amounts of radioactive materials bound to special compounds (radiopharmaceuticals) in combination with imaging scans that examine molecular processes in the body to detect and evaluate heart disease, brain disorders and cancer. In addition, radiopharmaceuticals are used to treat overactive thyroids and some cancers.


About SNM-Advancing Molecular Imaging and Therapy
SNM is an international scientific and professional organization of more than 16,000 members dedicated to promoting the science, technology and practical applications of molecular and nuclear imaging to diagnose, manage and treat diseases in women, men and children. Founded more than 50 years ago, SNM continues to provide essential resources for health care practitioners and patients; publish the most prominent peer-reviewed journal in the field (Journal of Nuclear Medicine); host the premier annual meeting for medical imaging; sponsor research grants, fellowships and awards; and train physicians, technologists, scientists, physicists, chemists and radiopharmacists in state-of-the-art imaging procedures and advances. SNM members have introduced-and continue to explore-biological and technological innovations in medicine that noninvasively investigate the molecular basis of diseases, benefiting countless generations of patients. SNM is based in Reston, Va.; additional information can be found online at http://www.snm.org.

Back to HCB News

More Industry Headlines